<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-529</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕГУЛЯТОРНЫЕ ВОПРОСЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REGULATORY ISSUES</subject></subj-group></article-categories><title-group><article-title>ТРЕНДЫ МИРОВОГО ФАРМАЦЕВТИЧЕСКОГО РЫНКА: НЕРЕАЛИЗОВАННЫЕ ВОЗМОЖНОСТИ РАЗВИТИЯ</article-title><trans-title-group xml:lang="en"><trans-title>GLOBAL PHARMACEUTICAL MARKET TRENDS: OPPORTUNITIES FOR DEVELOPMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демидёнок</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Demidyonok</surname><given-names>D. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrova</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наркевич</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Narkevich</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургская государственная химико-фармацевтическая академия» Минздрава России</institution></aff><aff xml:lang="en"><institution>St. Petersburg State Chemical and Pharmaceutical Academy of the Ministry of Healthcare</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>4</issue><fpage>282</fpage><lpage>287</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Демидёнок Д.А., Петрова Т.А., Наркевич И.А., Маркова В.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Демидёнок Д.А., Петрова Т.А., Наркевич И.А., Маркова В.А.</copyright-holder><copyright-holder xml:lang="en">Demidyonok D.A., Petrova T.A., Narkevich I.A., Markova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/529">https://www.pharmjournal.ru/jour/article/view/529</self-uri><abstract><p>Мировые расходы на здравоохранение достигнут к 2022 году 1,12 трлн долларов, что на 370 млрд долларов превысит уровень расходов в 2016 году. Текущие тенденции мирового фармацевтического рынка основаны на прорывных технологиях (disruptive technology), таких как редактирование генома, персонализация лекарственной терапии, инвестиции в нишевые области изучения и разработки лекарственных средств (орфанные препараты), увеличение сектора биотехнологий, использование системы обработки больших объемов данных (Big Data) и др.</p></abstract><trans-abstract xml:lang="en"><p>Global medicine spending will reach nearly $1.12 trillion by 2022 on an invoice price basis, up nearly $370 billion from the 2016 estimated spending level. Current trends are based on disruptive technologies including gene-editing, precision medicines and digital technologies, Big Data etc. The characteristics of biopharmaceutical innovation have also evolved over the past two decades, with increases in the share of cancer treatment launch, orphan indications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мировой фармацевтический рынок</kwd><kwd>персонализированная медицина</kwd><kwd>биотехнологии</kwd><kwd>био-фармпрепараты</kwd><kwd>орфанные препараты</kwd><kwd>прорывные технологии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>global pharmaceutical market</kwd><kwd>personalized (precision) medicine</kwd><kwd>Big Data</kwd><kwd>biotechnology</kwd><kwd>biopharmaceuticals</kwd><kwd>orphan drugs</kwd><kwd>disruptive technologies</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">JC. Scheeren. New approaches of regulating innovative medicines. Industry perspectives on regulating innovative medicines // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">JC. Scheeren. New approaches of regulating innovative medicines. Industry perspectives on regulating innovative medicines // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lifetime Trends in Biopharmaceutical Innovation // QuintilesIMS Institute. URL: http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/lifetime-trends-in-biopharmaceutical-innovation (дата обращения 26.07.2017).</mixed-citation><mixed-citation xml:lang="en">Lifetime Trends in Biopharmaceutical Innovation // QuintilesIMS Institute. URL: http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/lifetime-trends-in-biopharmaceutical-innovation (дата обращения 26.07.2017).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">L. Liberti. Exploring Innovative Regulatory Pathways: A US Perspective // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">L. Liberti. Exploring Innovative Regulatory Pathways: A US Perspective // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">HC. Mahler. Biologics Drug Product Development &amp; Manufacture: Current Challenges &amp; Innovation // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">HC. Mahler. Biologics Drug Product Development &amp; Manufacture: Current Challenges &amp; Innovation // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Personalized Medicine Coalition. Personalized Medicine at FDA, 2016. Progress Report.</mixed-citation><mixed-citation xml:lang="en">Personalized Medicine Coalition. Personalized Medicine at FDA, 2016. Progress Report.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">T. Salmonson. Future medicines: regulatory sciences // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">T. Salmonson. Future medicines: regulatory sciences // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Д.А. Демидёнок, В.А. Маркова. Перспективы использования метода 3D-печати для производства термолабильных лекарственных препаратов // Сборник материалов IV Всероссийской научно-практической конференции с международным участием «Инновации в здоровье нации». Санкт-Петербургская государственная химико-фармацевтическая академия. - Санкт-Петербург. 2016. С. 294-298.</mixed-citation><mixed-citation xml:lang="en">Д.А. Демидёнок, В.А. Маркова. Перспективы использования метода 3D-печати для производства термолабильных лекарственных препаратов // Сборник материалов IV Всероссийской научно-практической конференции с международным участием «Инновации в здоровье нации». Санкт-Петербургская государственная химико-фармацевтическая академия. - Санкт-Петербург. 2016. С. 294-298.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">European Medicines Agency. Identifying opportunities for «big data» in medicines development and regulatory science. Report from a workshop held by EMA on 14-15 November 2016. Р. 3-9.</mixed-citation><mixed-citation xml:lang="en">European Medicines Agency. Identifying opportunities for «big data» in medicines development and regulatory science. Report from a workshop held by EMA on 14-15 November 2016. Р. 3-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">А. Cave. Opportunities and Challenges for Big Data to Support Regulatory Decision Making // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">А. Cave. Opportunities and Challenges for Big Data to Support Regulatory Decision Making // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Т. Allvin. The Innovative pipelines of the pharmaceutical industry // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation><mixed-citation xml:lang="en">Т. Allvin. The Innovative pipelines of the pharmaceutical industry // 6th FIP Pharmaceutical Sciences World Congress, 2017. Швеция, Стокгольм.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">А.А. Сёмин. Анализ отечественного и зарубежного опыта по планированию и регулированию исследований в области фармацевтики // Кубанский научный медицинский вестник. 2017. № 3(24). C. 149-159.</mixed-citation><mixed-citation xml:lang="en">А.А. Сёмин. Анализ отечественного и зарубежного опыта по планированию и регулированию исследований в области фармацевтики // Кубанский научный медицинский вестник. 2017. № 3(24). C. 149-159.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
